Pfizer Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement schedule 14A, according to a recent SEC filing. This filing, which is not preliminary and requires no fee, is a standard procedure for publicly traded companies in compliance with Section 14(a) of the Securities Exchange Act of 1934. The materials are intended for Pfizer's shareholders and do not constitute soliciting material. This step indicates that Pfizer is preparing for upcoming engagements with its shareholders, although the specific contents of the materials were not disclosed in the announcement.

Pfizer Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement schedule 14A, according to a recent SEC filing. This filing, which is not preliminary and requires no fee, is a standard procedure for publicly traded companies in compliance with Section 14(a) of the Securities Exchange Act of 1934. The materials are intended for Pfizer's shareholders and do not constitute soliciting material. This step indicates that Pfizer is preparing for upcoming engagements with its shareholders, although the specific contents of the materials were not disclosed in the announcement.